NEW YORK, NY--(Marketwire - April 5, 2011) - Taglich Brothers, Inc. is pleased to announce that Richard Franco, President & CEO of DARA BioSciences, Inc. (
About Taglich Brothers
Taglich Brothers, Inc. is a full-service broker dealer focused exclusively on microcap companies. The Company defines the microcap segment of the equity market as companies with less than $250 million in market capitalization. Taglich Brothers currently offers institutional and retail brokerage services, investment banking and comprehensive research coverage to the investment community.
About DARA BioSciences, Inc.
DARA BioSciences, Inc. is a North Carolina based biopharmaceutical development company that acquires promising therapeutic candidates and develops them through proof of concept in humans for subsequent sale or out-licensing to larger pharmaceutical companies. Presently DARA has two drug candidates with cleared IND (Investigational New Drug) Applications from the United States FDA advancing through clinical development: 1. KRN5500 for the treatment of neuropathic pain; and 2. DB959 for the treatment of type 2 diabetes. In addition, the Company has a pipeline of diverse drug candidates at various stages of development, with 88 US and foreign granted patents and 60 pending applications. DARA owns CPT-1 inhibitors intended for topical application for patients with psoriasis, a library of DDPIV inhibitors and a diverse library of approximately 1800 PPAR agonists of various molecular modalities.
Contact Information:
Contact:
Taglich Brothers
Karen Payne
Symposia Events
212-779-2971